10-23DNAzyme capable of being orthogonally regulated and controlled by light-controlled organisms as well as preparation method and application of 10-23DNAzyme

By modifying DEACE and NPOM groups on 10-23 DNAzyme and activating and inactivating light irradiation at different wavelengths, multiple regulation of DNAzyme is achieved, solving the problem of inaccurate gene regulation time in the existing light control strategy, and improving the The accuracy and controllability of gene editing have the potential to apply in gene therapy and drug development.

CN118931906APending Publication Date: 2024-11-12LANZHOU JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411213755.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-08-20
Filing Date
2024-08-31
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing light control strategy can only realize the unidirectional activation or inactivate gene technology, but cannot achieve the multiple regulation of photo-controlled bioorthogonal reactions from 'OFF' to 'ON' and then to 'OFF', resulting in gene regulation time. Inaccurate.

Method used

By chemically modifying the DEACE and NPOM groups on 10-23 DNAzyme, DNAzyme is activated and inactivated by 450nm and 405nm light irradiation, multiple regulation of DNAzyme activity is achieved.

Benefits of technology

Multiple regulation of DNAzyme activity has been achieved, the accuracy and controllability of gene editing have been improved, the preparation process of DNAzyme is simplified, and its application potential in gene therapy and drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931906A_ABST
    Figure CN118931906A_ABST
Patent Text Reader

Abstract

The invention discloses 10-23DNAzyme capable of being subjected to light-controlled biological orthogonal regulation and a preparation method and application of the 10-23DNAzyme. Belongs to the technical field of functional nucleic acid regulation. The 10-23DNAzyme capable of regulating and controlling the activity in a light breakage mode is obtained by chemically modifying DNAzyme through light breakage groups NPOM and DEACM, the enzyme is in an inactivation inhibition state before illumination, is activated due to leaving of an inhibition chain after being irradiated by light with the wavelength of 450 nm, and is inactivated again due to breakage of a targeting binding arm after being irradiated by light with the wavelength of 405 nm again, so that the activity of the DNAzyme can be regulated and controlled. Therefore, the light-controlled biological orthogonal regulation and control method can be successfully applied to multiple regulation of DNAzyme activity. Besides, the light-controlled biological orthogonal reaction regulation and control method is simple and easy to implement, and the DNAzyme is easy to prepare, is expected to be developed into an important gene regulation and control tool, and plays an important role in the fields of gene therapy, drug development and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of functional nucleic acid regulation technology, and more specifically to a 10-23 DNA zyme capable of light-controlled bio-orthogonal regulation, and a preparation method and application thereof. Background Art

[0002] DNAzyme is a functional nucleic acid molecule with catalytic activity screened in vitro, which consists of two arbitrarily variable targeting binding arms and a 15-base conserved sequence ring catalytic center. 2+ 、Zn 2+ , Pb 2+ etc.) or other auxiliary factors to specifically catalyze and cleave substrate RNA, thereby blocking gene expression. Compared with nucleic acid tools such as CRISPR, DNAzyme is easier to synthesize and modify, has good chemical stability, low cost, is easier to enter the body, and is simpler to act on, so DNAzyme has developed into a highly potential biomolecular tool for regulating gene expression. After DNAzyme is introduced into cells, it can bind to the target mRNA through base complementary pairing, and then cut mRNA under the catalysis of metal ions, thereby reducing the expression of the corresponding protein and achieving the corresponding therapeutic purpose. Although DNAzyme has achieved many research results in gene regulation, the safety and effectiveness of in vivo applications caused by its possible off-target effects and uncontrollable activity are still bottlenecks that restrict its practical application. In response to these problems, it has become very necessary to design and develop conditionally responsive controlled DNAzymes to improve the accuracy and controllability of gene editing.

[0003] In the field of biological application technology, light has certain advantages as an exogenous condition control. Light is not only fast and efficient, clean, residue-free and has low cytotoxicity, but also can meet the requirements of precise control of nucleic acid functions in time and space. Therefore, it has become the most commonly used method for conditional control of nucleic acid functions. For example, by introducing photocaged bases at key positions of DNAzyme, a strategy of uncaging and activating DNAzyme by light irradiation. However, the main problem faced by these currently developed light-controlled strategies is that they can only achieve unidirectional control of gene expression by light in living organisms such as cells, that is, unidirectional activation or inactivation of gene technology by light, but cannot achieve multiple regulation of light-controlled bioorthogonal reactions from "OFF" to "ON" and then to "OFF" to manipulate gene technology at any time, resulting in the inability to accurately control the timing of gene regulation.

[0004] In summary, how to provide a method for multiple regulation of DNAzyme activity based on light-controlled bioorthogonal reactions is an urgent problem to be solved by those skilled in the art. Summary of the invention

[0005] In view of this, the present invention provides a 10-23 DNAzyme capable of light-controlled bioorthogonal regulation, and a preparation method and application thereof.

[0006] In order to achieve the above object, the present invention adopts the following technical solution:

[0007] A 10-23 DNAzyme capable of light-controlled bioorthogonal regulation, the nucleotide sequence of which is as follows:

[0008] 5'-TAG CTA GCC TCC CCA GCA GGA GGC TAG CTA CAA CGA CATGTGATC-3', SEQ ID NO.12;

[0009] DEACE is modified between the 12th and 13th bases, NPOM is modified between the 18th and 19th bases, and the bases at positions 13, 14, 15, 16, 17, 18, 38, 39, 40, 41, 42, 43, and 44 are thiolated.

[0010] The preparation method of the above-mentioned 10-23 DNAzyme comprises the following steps:

[0011] (1) Preparation of 7-diethylaminocoumarin (DEACM) phosphoramidite monomer II-1: 7-(diethylamino)-4-methylcoumarin is used as a starting material and reacted with DMF-DMA to obtain an enamine compound, which is then oxidized with NaIO4, reduced with sodium borohydride, protected with a 4,4-dimethoxytrityl (DMTr) group, and phosphorylated with 2-cyanoethoxy-N,N-diisopropylaminochlorophosphine (CEO(iPr)2NPCl) to obtain the 7-diethylaminocoumarin (DEACM) phosphoramidite target product (II-1);

[0012]

[0013] (2) Preparation of 6-nitropiperidinyloxymethyl (NPOM) phosphoramidite monomer II-2: 6-nitropiperidinyl aldehyde is used as a starting material to react with acetaldehyde and bis(3,5-bis(trifluoromethyl)phenyl)(pyrrolidin-2-yl)methanol, and then reduced with sodium borohydride to obtain the corresponding 1,3-diol compound; it is then protected by a 4,4,-dimethoxytrityl (DMTr) group and phosphorylated with 2-cyanoethoxy-N,N-diisopropylaminochlorophosphine (CEO(iPr)2NPCl) to obtain the 6-nitropiperidinyloxymethyl (NPOM) phosphoramidite target product (II-2);

[0014]

[0015] (3) Preparation of 10-23 DNAzyme modified with photocleavage groups NPOM and DEACM: Using phosphoramidite monomers II-1, II-2, A, G, C, and T as building blocks, phosphoramidite monomers II-1 and II-2 were modified into the DNAzyme chain by the phosphoramidite solid phase synthesis method using a nucleic acid solid phase synthesizer, and the photo-controllable bio-orthogonally regulated 10-23 DNAzyme was prepared by standard DNA synthesis procedures.

[0016] Furthermore, in step (3), the nucleic acid chain synthesized by solid phase needs to undergo a post-treatment step;

[0017] The post-treatment step is to cut the DNA chain product from CPG with 22% ammonia solution and incubate at 55°C for 12 hours; and then purify the crude DNA by high performance liquid chromatography using a PLRP-S column after ethanol precipitation to obtain 10-23DNAzyme.

[0018] A method for regulating the activity of 10-23 DNAzyme based on a light-controlled bioorthogonal reaction, using the above-mentioned 10-23 DNAzyme, is regulated under 450nm and / or 405nm light irradiation conditions. The regulation schematic diagram is as follows:

[0019]

[0020] in:

[0021] The metal ion used in 10-23 DNAzyme catalysis is Mg 2+ ;

[0022] The photoresponsive cleavage groups are 6-nitropiperidinyloxymethyl and 7-diethylaminocoumarin;

[0023] The light-controlled bioorthogonal reaction regulation method is: first activate 10-23DNAzyme with 450nm light, and then inactivate 10-23DNAzyme with 405nm light.

[0024] The above-mentioned 10-23 DNAzyme is used for RNA cleavage in vitro.

[0025] Furthermore, the sequence of the cleavage substrate is: 5'-GAU CACAUG G UCC UGC UGG-3', SEQ ID NO. 3; the 5' end is modified with FAM.

[0026] Application of the above-mentioned 10-23 DNAzyme in gene regulation in living cells.

[0027] Furthermore, the gene targeted in the living cells is GFP mRNA, and the nucleotide sequence of the GFP mRNA is shown in SEQ ID NO.13.

[0028] It can be seen from the above technical solution that, compared with the prior art, the beneficial effects achieved by the present invention are:

[0029] The present invention discloses a method and application for regulating DNAzyme activity based on light-controlled bio-orthogonal reaction. The DNAzyme is chemically modified by photo-cleavage groups NPOM and DEACM to obtain a 10-23DNAzyme whose activity can be regulated by photo-cleavage. The enzyme is in an inhibited and inactivated state before illumination. When treated with 450nm light, it is activated due to the inhibition of chain leaving. When irradiated with 405nm light again, it is inactivated again due to the breakage of the target binding arm. Thus, the light-controlled bio-orthogonal regulation method can be successfully applied to multiple regulation of DNAzyme activity. In addition, the light-controlled bio-orthogonal reaction regulation method is simple and easy, and DNAzyme is easy to prepare, and is expected to develop into an important gene regulation tool and play an important role in gene therapy and drug development. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0031] Figure 1 The synthetic route of 7-diethylaminocoumarin (DEACM) phosphoramidite monomer (II-1) in Example 1 of the present invention; wherein the reaction conditions of each step are: (i) DMF-DMA, DMF, 140°C; (ii) NaIO4, THF, CH2Cl2; (iii) 1) bis(3,5-bis(trifluoromethyl)phenyl)(pyrrolidin-2-yl)methanol, acetaldehyde, DMF. 2) NaBH4, CH3OH. (iv) DMTr-Cl, DMAP. (v) CH2Cl2, N, N-diisopropylethylamine, 2-cyanoethyl-N, N-diisopropylaminochlorophosphine;

[0032] Figure 2The synthetic route of 6-nitropiperidinyloxymethyl (NPOM) phosphoramidite monomer (II-2) in Example 2 of the present invention; wherein the reaction conditions of each step are: (i) 1) bis(3,5-bis(trifluoromethyl)phenyl)(pyrrolidin-2-yl)methanol, acetaldehyde, DMF. 2) NaBH4, CH3OH. (ii) DMTr-Cl, DMAP. (iii) CH2Cl2, N, N-diisopropylethylamine, 2-cyanoethyl-N, N-diisopropylaminochlorophosphine;

[0033] Figure 3 4 is the photocleavage reaction of the NPOM linker in Example 4 of the present invention under 405nm and 450nm light; wherein A represents a schematic diagram of the photocleavage of a DNA chain containing an NPOM linker; B represents a gel electrophoresis diagram of the photocleaved DNA chain;

[0034] Figure 4 The photocleavage reaction of the DEACM linker in Example 4 of the present invention under 405nm and 450nm light; wherein A represents a schematic diagram of the photocleavage of a DNA chain containing a DEACM linker; and B represents a gel electrophoresis diagram of the photocleaved DNA chain;

[0035] Figure 5 The light-induced unidirectional activation regulation of DNAzyme in Example 4 of the present invention; wherein A represents the schematic diagram of the light activation of 10-23 DNAzyme; B represents the effect of the length of the complementary chain at the 5' end of DNAzyme on its activity; C represents the light-induced activation of DNAzyme;

[0036] Figure 6 The light-induced unidirectional inactivation regulation of DNAzyme in Example 4 of the present invention; wherein A represents the schematic diagram of the light-controlled inactivation of 10-23 DNAzyme; B represents the effect of the length of the 5' end binding arm on the activity of DNAzyme; C represents the light-induced inactivation of DNAzyme;

[0037] Figure 7 This is the light-controlled bio-orthogonal multiple regulation of DNAzyme activity in Example 4 of the present invention; wherein A represents a schematic diagram of multiple regulation of DNAzyme activity by light; B represents a gel electrophoresis diagram of multiple regulation of DNAzyme activity by light;

[0038] Figure 8The cleavage kinetics of the DNAzyme modified with the photocleavage groups NPOM and DEACM in Example 4 of the present invention under different illumination conditions; wherein A represents the cleavage kinetics gel electrophoresis of the DNAzyme under no illumination conditions; B represents the cleavage kinetics gel electrophoresis of the DNAzyme under 405nm illumination conditions; C represents the cleavage kinetics gel electrophoresis of the DNAzyme under 450nm illumination conditions; D represents the cleavage kinetics gel electrophoresis of the DNAzyme under illumination conditions of 450nm light irradiation for 6 minutes and then 405nm light irradiation for 2 minutes; E represents the cleavage kinetics gel quantitative graph of the DNAzyme under different illumination conditions;

[0039] Fig. 9 The effect of light irradiation on the GFP protein level in living cells in Example 5 of the present invention; wherein A represents the effect of light irradiation on the GFP protein level in HEK293T cells; B represents the effect of light irradiation on the mRNA gene expression of GFP in HEK293T cells containing normal DNAzyme;

[0040] Fig.10 The light-induced DNAzyme activation in living cells in Example 5 of the present invention; wherein A represents a schematic diagram of light-induced DNAzyme activation regulation; B represents the gene regulation of GFP mRNA by light in HEK293T cells;

[0041] Fig.11 The light-induced DNAzyme inactivation in living cells in Example 5 of the present invention; wherein A represents a schematic diagram of light-induced DNAzyme inactivation regulation; B represents the gene regulation of GFP mRNA in HEK293T cells by light;

[0042] Fig.12 This is the multiple regulation of DNAzyme activity by light in living cells in Example 5 of the present invention; wherein A represents a schematic diagram of multiple regulation of DNAzyme activity by light; B represents multiple regulation of GFP mRNA gene by light in HEK293T cells;

[0043] Fig.13 It is a schematic diagram of the regulation of the present invention. DETAILED DESCRIPTION

[0044] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0045] The drugs required for the present invention are conventional experimental drugs, which are purchased from commercial channels; the experimental methods not mentioned are conventional experimental methods and will not be described in detail here.

[0046] Example 1

[0047] Preparation of 7-diethylaminocoumarin (DEACM) phosphoramidite monomer (II-1)

[0048]

[0049] Phosphoramidite monomer (II-1) is prepared according to Figure 1 The synthetic route was used for preparation.

[0050] (1) DMF-DMA (1.2 mL, 8.5 mmol) was added to a solution of 7-(diethylamino)-4-methylcoumarin (1) (1.9 g, 8.5 mmol) in dry DMF (10 mL) under nitrogen atmosphere. The mixture was heated to 140°C and stirred vigorously for 8 hours, and then more DMF-DMA (0.6 mL, 4.3 mmol) was added again. After heating for 8 hours, the solvent was removed by vacuum distillation. The residue was then suspended in cyclohexane (40 mL), filtered, washed with Et2O (40 mL), and dried in vacuo to obtain compound 2 (2.3 g) as a bright yellow powder with a yield of 95%.

[0051] (2) The enamine compound 2 (2.4 g, 8.5 mmol) was dissolved in a mixed solution of THF and CH2Cl2 (100 mL, 5 / 1, v / v). Then, a NaIO4 aqueous solution (5.5 g, 25.5 mmol) was added, and the resulting mixed reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure to obtain a crude product, which was then extracted with CH2Cl2 (3X 100 mL), and the combined organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by silica gel column chromatography (SiO2, 1:1 EtOAc / hexane) to obtain the desired compound 3 (1.6 g), which was dark red in color and had a yield of 81%.

[0052] (3) Compound 3 (1.23 g, 5 mmol), bis(3,5-bis(trifluoromethyl)phenyl)(pyrrolidin-2-yl)methanol (2.62 g, 5 mmol) and acetaldehyde (1.10 g, 25 mmol) were added to anhydrous DMF (10 mL) solution, and the reaction mixture was stirred at room temperature for 3 days. Then NaBH4 (189.15 mg, 5 mmol) and CH3OH (5 mL) were added to the reaction mixture, and stirred at 0°C for 2 hours. After the reaction was completed, saturated sodium chloride was added, extracted with CH2Cl2 three times, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (SiO2, 1:1 EtOAc / hexane) to obtain the desired product compound 4 (669.64 mg, 46%) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ (ppm): 7.41 (d, J = 9.1Hz, 1H), 6.58 (dd, J = 9.1, 2.5Hz, 1H), 6.51 (d, J = 2.6Hz, 1H), 6.36 (s, 1H), 5.29 (d, J = 8.0Hz,1H),4.03–3.90(m,2H),3.42(q,J=7.1Hz,4H),2.20–2.11(m,1H),1.95(dt,J=14.8,10.0Hz,1H),1.22(t,J=7.1Hz,6H); 13 C NMR (101MHz, CDCl3) δ (ppm): 163.0, 158.4, 156.4, 150.4, 124.8, 108.6, 106.0, 105.1, 97.9, 69.1, 60.9, 44.7, 38.4, 12.5.

[0053] (4) Compound 4 (291.15 mg, 1 mmol), DMAP (12.22 mg, 0.1 mol%) and DMTr-Cl (677.66 mg, 2 mmol) were dissolved in 5 ml of dry pyridine. The reaction mixture was stirred at room temperature for 12 hours under nitrogen. After the reaction was completed, the reaction solvent was removed by distillation under reduced pressure, and the residue was purified by flash column chromatography (SiO2, 1:2 EtOAc / hexane) to obtain the desired product 5 (379.70 mg, 64%) as a light yellow color. 1H NMR(400MHz, CDCl3)δ(ppm):7.47(d,J=7.6Hz,2H),7.41–7.31(m,8H),7.25(d,J=7.4Hz,1H),6.88(d,J=8.8Hz,4H),6.56–6.51(m,2H) ,6.29(s,1H),5.20(d,J=8.1Hz,1H),3.83(s,6H),3.42(q,J=7.0Hz,6H),2.24–2.16(m,1H),2.00–1.91(m,1H),1.22(t,J=7.0Hz,6H); 13 C NMR(101MHz, CDCl3)δ(ppm):162.4,158.6,157.6,156.5,150.2,144.6,135.8129.9,127.9,12 6.9,124.8,113.3,108.3,106.11,105.6,99.9,97.9,87.2,68.9,61.7,55.3,44.7,36.9,12.5.

[0054] (5) Compound 5 (593.28 mg, 1 mmol) was dissolved in dry CH2Cl2 (5 mL) in a round-bottom flask under nitrogen atmosphere. N, N-diisopropylethylamine (495.84 μL, 3 mmol) and 2-cyanoethyl-N, N-diisopropylaminochlorophosphine (444.86 μL, 2 mmol) were added to the reaction using a syringe, and the reaction was allowed to proceed at room temperature for 2 hours. After the reaction was completed, the reaction solvent was removed by distillation under reduced pressure, and the residue was purified by flash column chromatography (SiO2, 1:5 EtOAc / hexane, Et3N 1%) to obtain the desired product II-1 (618.84 mg, 78%) as a light yellow solid. 1H NMR (400MHz, CDCl3) δ7.66 (t, J=9.3Hz, 1H), 7.43 (dd, J=9.6, 7.7Hz, 2H), 7.35–7.28 (m, 6H), 7.23 (dt, J=9. 1,7.4Hz,1H),6.83(ddd,J=11.0,8.9,2.0Hz,4H),6.57–6.49(m,2H),6.14(d,J=27.0Hz,1H),5.32(s,1H), 3.81(d,J=4.5Hz,6H),3.75–3.48(m,4H),3.43(q,J=7.1Hz,4H),3.27(dddd,J=37.2,15.1,9.1,5.4Hz,2H) ,2.50–2.43(m,2H),2.25–2.07(m,2H),1.24(t,J=7.1Hz,6H),1.20–1.10(m,9H),1.03(d,J=6.8Hz,3H)ppm; 13 C NMR (151MHz, CDCl3) δ162.2,158.5,156.83(s),156.7,150.3,145.1,136.4,130.0,128.2,128.1,127.8,126.7,125.9,125.6,11 7.5,117.3,113.1,108.5,108.4,106.6,106.3,97.9,86.4,59.8,58.7,58.3,55.2,53.4,44.7,43.3,38.3,24.8,20.2,12.5ppm.

[0055] Example 2

[0056] Preparation of 6-Nitropiperidinyloxymethyl (NPOM) Phosphoramidite Monomer II-2

[0057]

[0058] Phosphoramidite monomer (II-2) is prepared according to Figure 2 The synthetic route was used for preparation.

[0059] (1) Compound 7 (975.10 mg, 5 mmol), bis(3,5-bis(trifluoromethyl)phenyl)(pyrrolidin-2-yl)methanol (2.62 g, 5 mmol) and acetaldehyde (1.10 g, 25 mmol) were added to anhydrous DMF (10 mL) solution, and the reaction mixture was stirred at room temperature for 3 days. Then NaBH4 (189.15 mg, 5 mmol) and CH3OH (5 mL) were added to the reaction mixture, and stirred at 0°C for 2 hours. After the reaction was completed, saturated sodium chloride was added, and the mixture was extracted three times with CH2Cl2, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (SiO2, 1:1 EtOAc / hexane) to obtain the desired product 8 (745.23 mg) as a yellow solid with a yield of 61%. 1 H NMR (400MHz, CDCl3) δ7.47 (s, 1H), 7.33 (s, 1H), 6.13 (d, J = 5.6Hz, 2H), 5.51 (dd, J=8.9,2.2Hz,1H),4.00–3.91(m,2H),2.07–2.01(m,1H),1.91–1.82(m,1H)ppm; 13 C NMR (101MHz, CDCl3) δ152.5,146.9,140.9,138.2,106.9,105.1,103.0,69.9,61.9,39.5ppm.

[0060] (2) Compound 8 (241.06 mg, 1 mmol), DMAP (12.22 mg, 0.1 mol%) and DMTr-Cl (677.66 mg, 2 mmol) were dissolved in 5 ml of dry pyridine. The reaction mixture was stirred at room temperature for 12 hours under nitrogen. The residue was purified by flash column chromatography (SiO2, 1:2 EtOAc / hexane) to give the desired product 9 (401.96 mg) as a yellow solid in a yield of 74%. 1 HNMR (400MHz, CDCl3) δ7.50–7.44(m,3H),7.37–7.31(m,7H),7.30–7.18(m,2H),6. 88(d,J=8.8Hz,4H),6.12(dd,J=6.0,5.3Hz,2H),5.49(d,J=8.0Hz,1H),4.12(d,J= 10.8Hz,1H),3.82(s,7H),3.49(td,J=9.1,3.3Hz,1H),3.41(ddd,J=9.6,5.6,3.9H z,1H),2.17(ddd,J=11.3,5.4,2.7Hz,1H),1.93(dtd,J=12.2,8.4,3.8Hz,1H)ppm;13 C NMR (101MHz, CDCl3) δ158.6),152.3,146.8,144.5,141.1,138.1,135.7,129.9,1 29.1,127.9,126.9,113.2,107.2,105.1,102.8,87.2,69.8,62.7,55.2,37.9ppm.

[0061] (3) Compound 9 (543.19 mg, 1 mmol) was dissolved in dry CH2Cl2 (5 mL) in a round-bottom flask under a nitrogen atmosphere. N, N-diisopropylethylamine (495.84 μL, 3 mmol) and 2-cyanoethyl-N, N-diisopropylamino chlorophosphine (444.86 μL, 2 mmol) were added to the reaction solution using a syringe, and the reaction was carried out under nitrogen for 2 hours. The residue was purified by flash column chromatography (SiO2, 1:5 EtOAc / hexane, Et3N 1%) to obtain the desired product II-2 (602.07 mg, 81%) as a light yellow solid. 1 H NMR (400MHz, CDCl3) δ7.66 (t, J=9.3Hz, 1H), 7.43 (dd, J=9.6, 7.7Hz, 2H), 7.35–7.28 (m, 6H), 7.23 (dt, J=9. 1,7.4Hz,1H),6.83(ddd,J=11.0,8.9,2.0Hz,4H),6.57–6.49(m,2H),6.14(d,J=27.0Hz,1H),5.32(s,1H), 3.81(d,J=4.5Hz,6H),3.75–3.48(m,4H),3.43(q,J=7.1Hz,4H),3.27(dddd,J=37.2,15.1,9.1,5.4Hz,2H) ,2.50–2.43(m,2H),2.25–2.07(m,2H),1.24(t,J=7.1Hz,6H),1.20–1.10(m,9H),1.03(d,J=6.8Hz,3H)ppm; 13C NMR (101MHz, CDCl3) δ158.6,158.3,152.0,146.9,145.2,141.1,139.5,13 7.4,136.5,130.1,129.1,128.2,127.9,127.1,126.6,117.6,117.3,113. 2,112.9,107.9,104.8,104.6,102.8,86.1,69.4,68.1,60.2,59.9,58.9, 58.7,58.1,57.9,55.2,53.5,43.2,39.6,31.5,30.2,29.7,24.5,24.1ppm.

[0062] Example 3

[0063] Synthesis of NPOM and DEACM modified nucleic acid sequences

[0064] II-1 and II-2 were introduced into the nucleic acid chain using a nucleic acid solid phase synthesizer.

[0065] Using phosphoramidite nucleoside monomers (II-1, II-2 and dA, dG, dC, dT) as synthetic units (wherein, phosphoramidite nucleoside monomers II-1 and II-2 are prepared according to the methods in Examples 1 and 2; phosphoramidite nucleoside monomers dA, dG, dC, dT are commercially available and purchased directly from a chemical reagent company), a conventional phosphoramidite solid phase synthesis method is used to sequentially couple II-1 and II-2 to a DNA chain in a set sequence order using a K&A H-8 DNA synthesizer, and then treated with a 22% ammonia solution and incubated at 55°C for 12 hours to remove the protective groups on the bases of the DNA chain. After ethanol precipitation, the PLRP-S column (250 mm×4.6 mm, The crude DNA was purified by high performance liquid chromatography (HPLC) to obtain the corresponding DNA chains (Table 1).

[0066] Table 1 Nucleotide sequences involved in the present invention

[0067]

[0068]

[0069] Note: DNA-DEACE refers to the DNA chain modified with 7-diethylaminocoumarin (DEACM); DNA-NPOM refers to the DNA chain modified with 6-nitropiperidinyloxymethyl (NPOM); DNAzyme-Sub refers to the substrate of DNAzyme; the dotted part represents the inhibitory chain; the underline represents the paired sequence of the inhibitory chain; the bold italic part represents the target binding arm.

[0070] Example 4

[0071] In vitro regulation of DNAzyme cleavage activity by light-controlled bioorthogonal reactions

[0072] (1) Photofragmentation nucleic acid verification

[0073] In order to verify the photo-cleavage effect of the photo-cleavage groups NPOM and DEACM designed by us, we used gel electrophoresis to analyze the 5'-FAM-labeled oligonucleotide sequences with modified NPOM and DEACM groups (sequences are shown in Table 1 for DNA-DEACE and DNA-NPOM) to characterize the photo-cleavage effect. Our gel electrophoresis experiment was performed by loading the samples before and after illumination into a 15% acrylamide gel through Loading Buffer, and electrophoresing at 150V for 30 minutes. After the electrophoresis was completed, the cleavage effect was analyzed on a gel imager (Amersham Image Quant 800).

[0074] As previous studies have shown that NPOM-modified photocleavable linkers are more sensitive to 405nm light and can be photocleaved in a short time, but are stable to 450nm light. Therefore, for 405nm light, we only studied the photocleavage within 3min, while for 450nm light, we studied the photocleavage for a longer time of less than 30min. Figure 3 The results of the illumination experiment shown in the figure indicate that (where the lower band represents the product after photofractionation, and the upper band represents DNA that has not undergone photofractionation. This is because illumination causes the molecular weight to change before and after the DNA chain breaks. When photofractionation occurs, the molecular weight decreases, so the electrophoretic mobility of the band is faster) that the NPOM group, which is a photocleavable linker, is rapidly cleaved in just 2 minutes under 405nm illumination, but no photofractionation occurs even when exposed to 450nm light for up to 30 minutes.

[0075] The photocleavable linker modified with DEACM group is sensitive to both 405nm and 450nm light. Therefore, the DEACM group can be cleaved regardless of whether 405nm or 450nm light is used. Figure 4 As shown in the figure, under 405nm light, it takes less than 1 minute to completely break, but under 450nm light, it takes longer, up to 15 minutes of exposure time to be completely cut. Figure 3 Compared with the NPOM group modified DNA strand breaks, Figure 4The DNA chain modified with DEACM groups produced two broken bands. This is mainly because the DEACM group is more sensitive to light and will undergo secondary photofragmentation, that is, the DNA breaks from the DEACM group after illumination. At the same time, some DEACM molecules will break again from the broken DNA chain, thus producing two break products.

[0076] In summary, the two photocleavage groups we selected are effective and can be used to manipulate the opening and closing of DNAzyme functions through subsequent photocleavage.

[0077] (2) Regulation of 10-23 DNAzyme cleavage activity in vitro

[0078] a. "OFF" to "ON" regulation: We verified whether it is possible to manipulate the activity of 10-23DNAzyme through a light-controlled bioorthogonal strategy in a biochemical in vitro cleavage assay. We first designed an "OFF" to "ON" regulation mode, that is, before illumination, the activity of 10-23DNAzyme was inhibited and inactive; after illumination, 10-23DNAzyme was activated. We introduced a complementary inhibitory strand by extending the 5' end of DNAzyme and connected it through a photo-cleavable linker (DEACM) to inhibit the activity of DNAzyme ( Figure 5 A) When exposed to light, the photocleavable linker breaks, the self-inhibitory strand leaves, and the DNAzyme is activated.

[0079] In order to better regulate the activity of DNAzyme, we optimized the length of the autoinhibitory chain. DNAzymes with inhibitory chains of 0, 6, 9, 12, and 15 nt in length were selected for RNA cleavage activity evaluation (enzyme and substrate sequences are shown in Table 1 for DNAzyme-0nt, DNAzyme-6nt, DNAzyme-9nt, DNAzyme-12nt, DNAzyme-15nt, and DNAzyme-Sub). Our in vitro cleavage experiments were performed in 20 mM tris-HCl, 10 mM Mg at pH 7.5. 2+ The reaction was carried out in a buffer solution of 100mM NaCl, where the ratio of enzyme to substrate was 2:1 (DNAzyme 1μM, substrate 0.5μM). After 30 minutes of reaction, gel electrophoresis was performed to evaluate the cleavage effect. When DNAzyme cleaves the substrate chain, the molecular weight decreases due to the breakage of the substrate chain, so the electrophoretic migration rate of the band is faster, resulting in the lower band being the band produced after the substrate is cleaved, and the upper band being the uncut substrate RNA. Figure 5As shown in Figure B, a 12nt or 15nt complementary inhibitory chain at the 5' end of DNAzyme is sufficient to inhibit the activity of DNAzyme. Considering that even if a longer chain breaks under light, it may not be easy to leave due to the large number of complementary sequences, which is not conducive to the photoactivation of DNAzyme, we chose a 12nt complementary inhibitory chain for the photoactivation experiment.

[0080] We then investigated whether the 5'-end inhibited DNAzyme could be activated by light. Figure 5 As shown in Figure C, compared with the normal control DNAzyme, the DNAzyme modified with the photocleavage group (DEACM) cannot bind to the substrate chain due to the inhibition of the complementary chain, and cannot cleave the RNA substrate in the absence of light. However, after irradiation at 405nm for 2min or 450nm for 6min, the DNAzyme regained its hybridization ability with the RNA substrate due to the cleavage of the inhibitory chain, and the activity of the DNAzyme was activated.

[0081] b. "ON" to "OFF" regulation: Similarly, we designed an "ON" to "OFF" regulation mode. We expect to introduce a photocleavable linker (NPOM) into the binding arm of the DNAzyme. Under light irradiation, the DNAzyme loses its targeting ability and becomes inactivated due to the cleavage of the targeting arm ( Figure 6 A).

[0082] First, we screened the photocleavage positions of the DNAzyme binding arms (sequences are shown in Table 1 for DNAzyme-NPOM-3nt, DNAzyme-NPOM-6nt, and DNAzyme-NPOM-9nt), as shown in Figure 6 As shown by the enzymatic cleavage activity of B, when the length of the binding arm at the 5' end of the DNAzyme was shortened to 3 nt, the enzyme almost lost its RNA cleavage activity. Therefore, the NPOM group as a photocleavable linker was placed at the third base upstream of the catalytic site of the 5'-binding arm to study our light inactivation regulation strategy.

[0083] We then verified the photoinactivation strategy, e.g. Figure 6 As shown in C, the control group can cleave the substrate RNA chain with or without light irradiation, showing efficient DNAzyme activity. For the DNAzyme with 5'-NPOM photocleavable linker modified binding arm, the cleavage activity of the DNAzyme is not affected in the absence of light irradiation. Only after 2 minutes of 405nm light, the DNAzyme loses its activity of cleaving RNA substrate due to the cleavage of the binding arm, and after 6 minutes of 450nm light irradiation, the photocleavable linker cannot be cleaved, so there is no effect on the activity of the enzyme.

[0084] c. Multiple regulation of "OFF" → "ON" → "OFF": In order to introduce multiple regulation of light-controlled bioorthogonal reactions of different wavelengths of light on the activity of DNAzyme, NPOM and DEACM groups were simultaneously modified on DNAzyme as photocleavable linking groups (sequence see DNAzyme-DEACE-NPOM in Table 1). DEACM was modified on the autoinhibitory chain, while NPOM was modified on the binding arm ( Figure 7 A) After irradiation with 450nm light, the DNAzyme in the "OFF" state is converted to the "ON" state due to the breakage of the DEACM linker, which causes the inhibitory chain to leave. If irradiated with 405nm light, the enzyme's cleavage activity will be inhibited again and return to the "OFF" state.

[0085] We verified this multiple light regulation result through gel electrophoresis experiments. For the control group, we directly mixed the enzyme and substrate without adding light and incubated them in the reaction buffer for 30 minutes. For the experimental group modified with dual photosensitizers, we added the modified DNAzyme in the initial "OFF" state to three equal reaction tubes and performed different light operations. For the first enzyme sample, we kept it in the dark without adding any light, for the second enzyme sample, we only used 450nm light for 6 minutes, and for the third enzyme sample, we first used 450nm light for 6 minutes and then 405nm light for 2 minutes. After the different light treatments were completed, all enzyme samples were mixed with the substrate and incubated in the reaction buffer for 30 minutes. Finally, the reacted samples were analyzed by gel electrophoresis.

[0086] like Figure 7 As shown in B, the control group showed efficient enzyme cleavage activity on the substrate without light irradiation ( Figure 7 B, Lane 1). However, the experimental group modified with dual photosensitive groups showed almost no activity when there was no light ( Figure 7 B, Lane 2); when irradiated with 450nm light for 6min, the enzyme activity was activated and the substrate was effectively broken down ( Figure 7 B, Lane 3). After irradiation at 450 nm for 6 min, the enzyme lost its activity again, so no substrate breakage was observed in the gel image ( Figure 7 B, Lane 4). This indicates that we have achieved the activation of DNAzyme and the light-controlled bio-orthogonal multiple regulation of activation and light-induced inactivation.

[0087] We then conducted gel dynamics experiments to verify our photomanipulation process. Figure 8The kinetic data of the RNA cleavage experiment show the changes in the activity of the dual-modified DNAzyme without light irradiation or under 450nm light irradiation, 405nm light irradiation or dual light irradiation (sequences are shown in Table 1 DNAzyme-DEACE-NPOM). Obviously, in the absence of light, the dual-photosensitive group-modified DNAzyme is in a self-inhibited state and does not show RNA cleavage activity ( Figure 8 A); After irradiation with 405 nm light, the DNAzyme cannot bind to the substrate due to the breakage of the binding arm, resulting in it remaining in an inactive state ( Figure 8 B); After irradiation with 450nm light, the DNA enzyme binding arm can bind to the RNA substrate chain due to the breakage of the inhibitory chain, resulting in the activation of the DNA enzyme, and the amount of total RNA cut gradually increases over time ( Figure 8 C); however, after irradiation with 450nm light for 6 minutes, when irradiated with 405nm light for 2 minutes, the self-inhibited complementary chain connected to the DEACM group was broken due to the irradiation of 450nm light, making the DNA enzyme active. However, after irradiation with 405nm light for 2 minutes again, the DNAzyme binding arm connected to the NPOM group was broken, making the DNAzyme inactivated again, and finally the RNA stopped breaking after being cut by about 50% ( Figure 8 D).

[0088] Figure 8 E clearly presents the Figure 8 A~ Figure 8 The gel quantification results of RNA cleavage by D. When irradiated with 450nm light and 405nm light respectively, RNA fragmentation first increased and then remained constant at about 50%, which is consistent with the result that DNAzyme is first activated and then inactivated by light irradiation for 10-23 seconds. This further shows that we have achieved the activation of DNAzyme and the light-induced inactivation after activation.

[0089] Example 5

[0090] A method for regulating DNAzyme activity based on light-controlled bioorthogonal reactions and its application in gene regulation

[0091] (1) We tested whether a light-controlled bioorthogonal strategy could be used to manipulate DNAzyme-mediated gene regulation in living cells. The DNAzyme sequence was designed to target unstable GFP (dsGFP) mRNA (nucleotide sequence as follows), and a phosphorothioate bond was introduced into the DNAzyme binding arm to enhance its effect. Before validating our light-controlled bioorthogonal strategy, we first verified the effect of light irradiation on the GFP protein expression level in HEK293T cells, as well as the effect of light irradiation on the mRNA gene expression of GFP in HEK293T cells containing normal DNAzyme, to exclude the possible interference of light irradiation on cell experiments.

[0092] After we treated HEK293T cells with 405nm for 3min and 450nm for 20min, we continued to culture them for 24h and then detected the GFP protein level. Fig. 9 As shown in A, the GFP protein levels of HEK293T cells treated with light and those without light are basically the same, indicating that the effect of light on HEK293T cells can be ignored and does not affect the GFP protein level of cells.

[0093] We then investigated whether light would affect the expression of GFP mRNA in HEK293T cells containing normal DNAzyme (sequences are shown in Table 1 for DNAzyme). Similarly, we irradiated the cells with 405nm light for 3min and then with 450nm light for 20min. The cells were then cultured for 24h and the GFP mRNA levels were measured. Fig. 9 As shown in B, illumination also had no effect on GFP in HEK293T cells containing DNAzyme.

[0094] (2) Considering the 3 min 405 nm and 20 min 450 nm light (16 mW / cm 2 ) to irradiate cells, and it does not affect the function of DNA enzymes in cells. Therefore, we verified our light activation strategy in cells under this condition. Before illumination, we first transfected the inactivated DNAzyme modified with DEACM photocleavable linker into cells with lipo300. After culturing the cells for 6 hours, we irradiated them with 405nm for 3min and 450nm for 20min (16mW / cm 2 ) were used to irradiate the treated cells, and the dsGFP level was measured after 18 hours of incubation. Fig.10 As shown, the modified 5′-end inhibitory DNAzyme restored the cleavage activity and knocked down the expression of dsGFP by 405 nm or 450 nm light irradiation, showing a highly efficient light-induced “turn-on” effect (sequence see DNAzyme-DEACE in Table 1 ).

[0095] To achieve light-induced inactivation, a similar process was performed as described above, except that the DNAzyme was designed to insert an NPOM group as a photocleavable linker in the 5' binding arm ( Fig.11 ) (sequence see DNAzyme-NPOM in Table 1), in the presence of modified DNAzyme in cells, the original enzyme remained active in the absence of light irradiation (Dark), knocking down GFP expression. In sharp contrast, after 405nm light irradiation, GFP expression was restored, while 450nm light had no effect on GFP expression, clearly indicating that the function of DNAzyme was induced to be inactivated ("OFF") by 405nm light.

[0096] (3) Finally, we intend to simultaneously introduce DNAzymes modified with NPOM and DEACM groups into cells as photocleavable linkers to achieve multiple regulation of DNAzyme function ( Fig.12 ) (sequence see DNAzyme-DEACE-NPOM in Table 1). The cells were cultured for 6 hours before light irradiation. Subsequently, 450nm light was selected to treat the cells, and part of the cell sample was irradiated again with 405nm light after an interval of 10 hours. The expression level of GFP was determined after another 16 hours of incubation. If only 450nm light was used, the expression of GFP was inhibited; but after 10 hours of continued irradiation with 405nm light, the expression level of GFP returned to the level without light. Overall, these GFP expression data show that the photoorthogonal strategy can be successfully applied to multiple regulation of DNAzyme activity.

[0097] Among them, the gene targeted in living cells is GFP mRNA (d2EGFP mRNA):

[0098] 5’-AUGGUGAGCAAGGGCGAGGAGCUGUUCACCGGGGUGGUGCCCAUCCUGGU CGAGCUGGACGGCGACGUAAACGGCCACAAGUUCAGCGUGUCCGGCGAGGGCGAGGGCGAUGCCACCUACGGCAAGCUGACCCUGAAGUUCAUCUGCACCACCGGCAAGCUGCCCGUGCCCUGGCCCACCCUCGUGACCACCCUGACCUACGGCGUGCAGUGCUUCAGCCGCUACCCCGACCACAUGAAGCAGCACGACUUCUUCAAGUCCGCCAUGCCCGAAGGCUACGUCCAGGAGCGCACCAUCUUCUUCAAGGACGACGGCAACUACAAGACCCGCGCCGAGGUGAAGUUCGAGGGCGACACCCUGGUGAACCGCAUCGAGCUGAAGGGCAUCGACUUCAAGGAGGACGGCAACAUCCUGGGGCACAAGCUGGAGUACAACUACAACAGCCACAACGUCUAUAUCAUGGCCGACAAGCAGAAGAACGGCAUCAAGGUGAACUUCAAGAUCCGCCACAACAUCGAGGACGGCAGCGUGCAGCUCGCCGACCACUACCAGCAGAACACCCCCAUCGGCGACGGCCCCGUGCUGCUGCCCGACAACCACUACCUGAGCACCCAGUCCGCCCUGAGCAAAGACCCCAACGAGAAGCGCGAUCACAUGGUCCUGCUGGAGUUCGUGACCGCCGCCGGGAUCACUCUCGGCAUGGACGAGCUGUACAAGAAGCUUAGCCAUGGCUUCCCGCCGGAGGUGGAGGAGCAGGAUGAUGGCACGCUGCCCAUGUCUUGUGCCCAGGAGAGCGGGAUGGACCGUCACCCUGCAGCCUGUGCUUCUGCUAGGAUCAAUGUGUAG-3’, SEQ ID NO.13;

[0099] Among them, the bold sequence is the targeting sequence.

[0100] In the present invention, we modified DNAzyme with two photocleavable linkers (NPOM and DEACM) of different wavelengths to achieve the regulation mode of light-controlled DNAzyme from "ON" to "OFF" or "OFF" to "ON" in living cells. In addition, multiple regulation from "OFF" to "ON" and then to "OFF" can be achieved by activating it with light and then deactivating it with light of another wavelength, which will provide a reliable method for light-controlled gene expression.

[0101] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.

[0102] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A 10-23 DNAzyme capable of light-controlled bioorthogonal regulation, characterized in that: Its nucleotide sequence is as follows: 5'-TAG CTA GCC TCC CCA GCA GGA GGC TAG CTA CAA CGA CATGTGATC-3', SEQ IDNO.12; DEACE is modified between the 12th and 13th bases, NPOM is modified between the 18th and 19th bases, and the bases at positions 13, 14, 15, 16, 17, 18, 38, 39, 40, 41, 42, 43, and 44 are thiolated.

2. The method for preparing the 10-23 DNAzyme according to claim 1, characterized in that: The steps include: (1) Preparation of 7-diethylaminocoumarin (DEACM) phosphoramidite monomer II-1: 7-(diethylamino)-4-methylcoumarin is used as a starting material and reacted with DMF-DMA to obtain an enamine compound, which is then oxidized with NaIO4, reduced with sodium borohydride, protected with a 4,4-dimethoxytrityl (DMTr) group, and phosphorylated with 2-cyanoethoxy-N,N-diisopropylaminochlorophosphine (CEO(iPr)2NPCl) to obtain the 7-diethylaminocoumarin (DEACM) phosphoramidite target product (II-1); (2) Preparation of 6-nitropiperidinyloxymethyl (NPOM) phosphoramidite monomer II-2: 6-nitropiperidinyl aldehyde is used as a starting material to react with acetaldehyde and bis(3,5-bis(trifluoromethyl)phenyl)(pyrrolidin-2-yl)methanol, and then reduced with sodium borohydride to obtain the corresponding 1,3-diol compound; it is then protected by a 4,4,-dimethoxytrityl (DMTr) group and phosphorylated with 2-cyanoethoxy-N,N-diisopropylaminochlorophosphine (CEO(iPr)2NPCl) to obtain the 6-nitropiperidinyloxymethyl (NPOM) phosphoramidite target product (II-2); (3) Preparation of 10-23 DNAzyme modified with photocleavage groups NPOM and DEACM: Using phosphoramidite monomers II-1, II-2, A, G, C, and T as building blocks, phosphoramidite monomers II-1 and II-2 were modified into the DNAzyme chain by the phosphoramidite solid phase synthesis method using a nucleic acid solid phase synthesizer, and the photo-controllable bio-orthogonally regulated 10-23 DNAzyme was prepared by standard DNA synthesis procedures.

3. The preparation method according to claim 2, characterized in that: In step (3), the nucleic acid chain synthesized by solid phase synthesis needs to undergo a post-treatment step; The post-treatment step is to cut the DNA chain product from CPG with 22% ammonia solution and incubate at 55°C for 12 hours; and then purify the crude DNA by high performance liquid chromatography using a PLRP-S column after ethanol precipitation to obtain 10-23DNAzyme.

4. A method for regulating 10-23 DNAzyme activity based on light-controlled bioorthogonal reaction, characterized in that: The 10-23 DNAzyme according to claim 1 is used for regulation under 450nm and / or 405nm light irradiation conditions. The regulation schematic diagram is as follows: in: The metal ion used in 10-23 DNAzyme catalysis is Mg 2+ ; The photoresponsive cleavage groups are 6-nitropiperidinyloxymethyl and 7-diethylaminocoumarin; The light-controlled bioorthogonal reaction regulation method is: first activate 10-23DNAzyme with 450nm light, and then inactivate 10-23DNAzyme with 405nm light.

5. Use of the 10-23 DNAzyme according to claim 1 in in vitro RNA cleavage.

6. The use according to claim 5, characterized in that The sequence of the cleavage substrate is: 5'-GAU CAC AUG GUCCUGC UGG-3', SEQ ID NO. 3; the 5' end is modified with FAM.

7. Use of the 10-23 DNAzyme according to claim 1 in gene regulation in living cells.

8. The use according to claim 7, characterized in that The gene targeted in the living cells is GFP mRNA, and the nucleotide sequence of the GFP mRNA is shown in SEQ ID NO.13.